癌症单株抗体的共同研究及授权契约:2016年～2025年

"癌症单株抗体合作与授权协议" 报告提供了全球领先生物製药公司达成的癌症单株抗体交易的全面了解和前所未有的管道。

本报告详细介绍了2016年至2025年癌症单株抗体交易，并详细分析了该公司达成癌症单株抗体交易的方式和原因。这些交易通常包含多个要素，从合作研发到成果商业化。

本报告涵盖了合作、开发、研究和授权交易。

本报告包​​含自2016年以来宣布的632项癌症单株抗体交易的完整列表，并包含交易方披露的实际癌症单株抗体合作交易的线上交易记录连结。此外，如有公司及其合作伙伴向美国证券交易委员会提交的合约文件，报告也会记录在案。

本报告第一章介绍了单株抗体 (MOA) 交易。

第一章是对报告的介绍。

第二章概述了自 2016 年以来单株抗体 (MOA) 交易的趋势。

第三章概述了自 2016 年以来的主要单株抗体 (MOA) 交易。交易按总价值列出。

第四章提供了在单株抗体 (MOA) 交易中最活跃的 25 家公司的综合列表，随后是简要摘要、单株抗体 (MOA) 交易的综合列表以及公开的交易文件。

第五章全面深入地回顾了自2016年1月以来已完成或宣布的单株抗体 (MOA) 交易，并已公开交易文件。

第六章全面深入地回顾了自2016年1月以来已完成和宣布的所有单株抗体 (mAb) 合作交易。本章按感兴趣的特定单株抗体 (mAb) 技术类型进行组织。

报告中还包含大量图表和数据，显示了自2016年以来单株抗体 (mAb) 交易的趋势和活动。

此外，一份全面的交易目录按公司 A-Z、交易类型和治疗目标进行组织。每个交易标题都透过网页连结连结到线上交易记录以及合约文件（如有），以便轻鬆按需存取每个合约文件。

主要的优点

"癌症单株抗体合作与授权协议" （简称 "癌症单株抗体合作与授权协议" ）为读者提供以下主要优势：

• 了解自2016年以来的合约趋势
• 浏览癌症单株抗体合作与授权交易
• 基准分析 - 确定交易的市场价值
• 财务条款 - 一次性付款、里程碑付款、特许权使用费
• 依公司A-Z、交易类型及治疗领域排列的交易目录
• 主要交易价值
• 最活跃的交易者
• 确定每笔交易的资产和交易条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款是否适合您的合作伙伴公司
• 节省数百小时的研究时间

调查范围

• "肿瘤单株抗体合作与许可协议" 旨在深入了解世界领先生物製药公司签署的肿瘤单株抗体趋势和交易结构。

"肿瘤单株抗体合作与授权协议" 包括：

• 生物製药产业的肿瘤单株抗体交易趋势
• 涵盖製药和生物技术领域的肿瘤单株抗体交易记录目录
• 主要的肿瘤单株抗体交易
• 最活跃的肿瘤单株抗体许可公司
• "肿瘤单株抗体合作与授权协议" 提供全面的交易记录，包括合约文件。

分析合约有助于进行以下方面的尽职调查：

• 授予或选择的具体权利是什么？
• 合约伙伴实际上被授予了什么？
• 授予了哪些独家权利？
• 合约的付款结构是怎样的？
• 如何审计销售和付款？
• 合约期限是多久？
• 合约的关键条款是如何界定的？
• 如何处理和归属知识产权？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密与揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更会怎样？
• 双方约定了哪些分授权或分包条款？
• 公司坚持哪些样板条款？
• 哪些样板条款似乎因合作伙伴和交易类型而异？
• 公司在契约法方面主张哪些管辖权？

目录

摘要整理

第1章 简介

第2章 癌症单株抗体交易趋势

• 简介
• 多年的癌症单株抗体交易
• 最活跃的癌症单株抗体交易业者
• 癌症单株抗体交易，各交易类型
• 癌症单株抗体交易，各治疗领域
• 癌症单株抗体交易，各业界
• 癌症单株抗体交易的交易条件
  • 癌症单株抗体交易的标题金额
  • 癌症单株抗体交易预付款
  • 癌症单株抗体交易的里程金
  • 癌症单株抗体的特许权费用率

第3章 -主要癌症单株抗体交易

• 简介
• 主要的癌症单株抗体交易，各金额

第4章 -最活跃的癌症单株抗体交易业者

• 简介
• 最活跃的癌症单株抗体交易业者
• 最活跃的癌症单株抗体交易企业简介

第5章 -癌症单株抗体契约交易名录

• 简介
• 癌症单株抗体契约交易名录

第6章 癌症单株抗体的各技术交易

• 交易名录
• 交易名录- 癌症单株抗体交易，各企业
• 交易名录- 癌症单株抗体交易，各交易类型
• 交易名录- 癌症单株抗体交易，各治疗领域
• 交易类型定义
• 关于调查公司
• 目前联盟
• 目前契约
• 最近的报告标题

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 632 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cancer monoclonal antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cancer Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Monoclonal Antibody Collaboration and Licensing Deals includes:

• Trends in cancer monoclonal antibody dealmaking in the biopharma industry
• Directory of cancer monoclonal antibody deal records covering pharmaceutical and biotechnology
• The leading cancer monoclonal antibody deals by value
• Most active cancer monoclonal antibody licensing dealmakers
• Cancer Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

• 2.1. Introduction
• 2.2. Cancer monoclonal antibody deals over the years
• 2.3. Most active cancer monoclonal antibody dealmakers
• 2.4. Cancer monoclonal antibody deals by deal type
• 2.5. Cancer monoclonal antibody deals by therapy area
• 2.6. Cancer monoclonal antibody deals by industry sector
• 2.7. Deal terms for cancer monoclonal antibody deals
  • 2.7.1 Cancer monoclonal antibody deals headline values
  • 2.7.2 Cancer monoclonal antibody deal upfront payments
  • 2.7.3 Cancer monoclonal antibody deal milestone payments
  • 2.7.4 Cancer monoclonal antibody royalty rates

Chapter 3 - Leading cancer monoclonal antibody deals

• 3.1. Introduction
• 3.2. Top cancer monoclonal antibody deals by value

Chapter 4 - Most active cancer monoclonal antibody dealmakers

• 4.1. Introduction
• 4.2. Most active cancer monoclonal antibody dealmakers
• 4.3. Most active cancer monoclonal antibody deals company profiles

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type

• Deal directory
• Deal directory - Cancer monoclonal antibody deals by company A-Z
• Deal directory - Cancer monoclonal antibody deals by deal type
• Deal directory - Cancer monoclonal antibody deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cancer monoclonal antibody deals since 2016
• Figure 2: Active cancer monoclonal antibody dealmaking activity - 2016 - 2025
• Figure 3: Cancer monoclonal antibody deals by deal type since 2016
• Figure 4: Cancer monoclonal antibody deals by therapy area since 2016
• Figure 5: Cancer monoclonal antibody deals by industry sector since 2016
• Figure 6: Cancer monoclonal antibody deals with a headline value
• Figure 7: Cancer monoclonal antibody deals with an upfront value
• Figure 8: Cancer monoclonal antibody deals with a milestone value
• Figure 9: Cancer monoclonal antibody deals with a royalty rate value
• Figure 10: Top cancer monoclonal antibody deals by value since 2016
• Figure 11: Most active cancer monoclonal antibody dealmakers 2016 - 2025
• Figure 12: Cancer monoclonal antibody deals by technology type since 2016